Zika virus protease inhibitors and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11517581-B2
Application number	US-201716606877-A
Country	US
Kind code	B2
Filing date	Jun 15, 2017
Priority date	Apr 20, 2017
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.

First claim

We claim:

1. A method for treating Zika virus infection, the method comprising:
administering, to a subject suffering from, or being at risk of developing, Zika virus infection, an effective amount of a composition that inhibits Zika virus protease,
wherein the composition comprises novobiocin, rifampicin, desmopressin acetate, octreotide acetate, or any combination thereof.

2. The method of claim 1 , wherein the amount of the composition is effective to inhibit Zika virus protease in the subject.

3. The method of claim 1 , wherein the subject is an adult.

4. The method of claim 1 , wherein the subject is pregnant.

5. The method of claim 1 , wherein the subject is immune compromised.

6. The method of claim 1 , wherein the composition comprises novobiocin and lopinavir-ritonavir.

7. The method of claim 1 , wherein the composition comprises an effective amount of novobiocin, wherein the effective amount of novobiocin is less than 300 mg/kg/d.

8. The method of claim 1 further comprising, prior to administering, diagnosing the subject as suffering from, or being at risk of developing, Zika virus infection.

9. The method of claim 1 , wherein the subject is suffering from Zika virus infection, wherein the amount of the composition administered to the subject is an amount effective to treat the Zika virus infection in the subject.

Assignees

• Versitech Ltd
• Fundacion Univ San Antonio

Inventors

• Yuan Shuofeng
• Chan Fuk Woo Jasper
• Yuen Kwok Yung
• Den Haan Helena
• Pena-García Jorge
• Pedro Cerón-Carrasco José
• Emilio Pérez-Sánchez Horacio

Classifications

• A61P31/14 Primary

  for RNA viruses · CPC title

• G01N2333/9513

  derived from RNA viruses · CPC title

• A61K31/7048 Primary

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12Q1/37

  involving peptidase or proteinase · CPC title